Impact of a novel digital therapeutics system on nonalcoholic steatohepatitis: the NASH App clinical trial

Management of nonalcoholic steatohepatitis (NASH) is a currently unmet clinical need. Digital therapeutics (DTx) is an emerging class of medicine that delivers evidence-based therapeutic interventions. The current study was aimed at investigating the efficacy of DTx in patients with NASH.


We conducted a multicenter, single-arm, 48-week trial in 20 patients with biopsy-confirmed NASH. All patients received a DTx intervention with a newly developed smartphone application. The primary endpoint was change in the nonalcoholic fatty liver disease activity score (NAS) without worsening of liver fibrosis. The secondary endpoints included improvement of the NAS by ≥2 points without worsening of liver fibrosis, change in the body weight, and regression of fibrosis.


After the 48-week DTx intervention, improvement of the NAS was observed in 68.4% (13/19) of patients. The mean change in the NAS from the baseline to the end of the intervention was -2.05 ± 1.96 (p = 0.007 as compared with the threshold of -0.7). A decrease of the NAS by ≥2 points was achieved in 11 (57.9%). The average weight loss at the end of the intervention was 8.3% (p < 0.001). Reduction of the fibrosis stage was observed in 58.3% when the analysis was limited to patients with stage F2/3 fibrosis. There were no serious adverse events that could be considered as being related to the DTx intervention.


DTx for NASH was found to be highly efficacious and well-tolerated. Further evaluation of the DTx intervention for NASH in a phase III trial is warranted